Onxeo to Present at the 18th Annual Rodman and Renshaw Global Investment Conference in New York

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specialized in the development of orphan oncology therapeutics, today announced that Company management is scheduled to present at the 18th Annual Rodman & Renshaw Global Investment Conference, being held September 11-13, 2016 at the Lotte New York Palace Hotel in New York, NY.

During the presentation, Onxeo management will discuss recent clinical and operational milestones and its outlook for the future, including its clinical development plans for recently-acquired lead signal-interfering DNA product candidate AsiDNA™, updates on the ongoing Phase III ReLive trial of Livatag® and new steps in product development and commercialization of Beleodaq® including international expansion.

Details of the presentation are as follows:

  • Date: Monday, September 12
  • Time: 2:10 – 2:35 PM EDT
  • Location: Roswell (4th Floor)

Download PDF